
LCTX Stock Forecast & Price Target
LCTX Analyst Ratings
Bulls say
Lineage Cell Therapeutics is positioned for success with its innovative pipeline of cell-based therapies, particularly OpRegen which has shown positive data in the treatment of AMD, a large unmet need in the medical community. Partnering with Roche and Genentech lends support and credibility to the potential of these therapies, and the company's proprietary AlloSCOPE platform provides a strong foundation for commercialization and scalability. Meanwhile, the reported improvements in visual and anatomical measures demonstrate the potential for meaningful disease stabilization and functional improvement in a historically irreversible condition, positioning Lineage Cell Therapeutics as a frontrunner in the biotechnology space.
Bears say
Lineage Cell Therapeutics is facing several risk factors, including clinical, regulatory, financial, commercial, legal, and market share risks, which could all potentially impact the success of their pipeline programs and overall financial performance. The company's AlloSCOPE manufacturing platform and TAI formulation may offer some potential advantages, but they have not yet been proven to be more effective than traditional cell therapy methods. Additionally, the company's current financial stability and market share are uncertain, especially given the volatility of the biotechnology industry.
This aggregate rating is based on analysts' research of Lineage Cell Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LCTX Analyst Forecast & Price Prediction
Start investing in LCTX
Order type
Buy in
Order amount
Est. shares
0 shares